Navigation Links
Regulus Announces Significant Progress in Strategic Alliance with AstraZeneca and Selection of a New Pre-Clinically Validated microRNA Oncology Target
Date:10/28/2013

LA JOLLA, Calif., Oct. 28, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the selection of an undisclosed oncology target by AstraZeneca under the strategic alliance to discover, develop, and commercialize microRNA therapeutics.  Regulus and AstraZeneca continue to collaborate on three exclusive microRNA targets in cardiovascular and metabolic diseases and oncology.

"We are very pleased with the successful relationship we have built with AstraZeneca and their selection of a validated microRNA target for oncology indications," said Neil W. Gibson, Ph.D., Chief Scientific Officer of Regulus.  "In the last year, we have made significant progress in advancing our drug discovery efforts against the portfolio of AstraZeneca targets.  With the support of AstraZeneca's drug development expertise and commitment to the RNA therapeutics field, we continue to harness our microRNA expertise to develop innovative, first-in-class treatment options for patients in need." 

In August 2012, Regulus and AstraZeneca formed a strategic alliance focused on three exclusive microRNA targets for cardiovascular and metabolic diseases and oncology, which includes Regulus' program targeting microRNA-33 for the treatment of atherosclerosis.  Under the terms of the alliance, Regulus will lead preclinical development and, if successful, could receive preclinical milestone payments.  AstraZeneca will lead and fund the clinical development and commercialization of these programs.  In addition, Regulus could also receive clinical milestones based on the successful development of microRNA therapies in each target area. Regulus is also eligible to receive significant launch and commercial milestone payments and royalties contingent on the successful commercialization of microRNA therapeutic products by AstraZeneca.

About Regulus Therapeutics Inc.

Regulus Therapeutics Inc. (NASDAQ: RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus is uniquely positioned to leverage a mature therapeutic platform that harnesses the oligonucleotide drug discovery and development expertise of Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc., which founded the company.   Regulus has a well-balanced microRNA therapeutic pipeline entering clinical development, an emerging microRNA biomarkers platform to support its therapeutic programs, and a rich intellectual property estate to retain its leadership in the microRNA field.  Regulus intends to focus its proprietary efforts on developing microRNA therapeutics for oncology indications and orphan diseases and is currently advancing several programs toward clinical development in oncology, fibrosis and metabolic diseases.  Regulus is also developing RG-101, a GalNAc-conjugated anti-miR targeting microRNA-122, for the treatment of chronic hepatitis C virus infection.  Regulus' commitment to innovation and its leadership in the microRNA field have enabled the formation of strategic alliances with AstraZeneca, GlaxoSmithKline and Sanofi.  In addition, Regulus has formed a research collaboration with Biogen Idec around its emerging microRNA biomarkers platform. 

For more information, please visit http://www.regulusrx.com

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with Regulus' expectations regarding future therapeutic and commercial potential of Regulus' business plans, technologies and intellectual property related to microRNA therapeutics being discovered and developed by Regulus.  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Regulus' current expectations and involve assumptions that may never materialize or may prove to be incorrect.  Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  These and other risks concerning Regulus' programs are described in additional detail in Regulus' SEC filings.  All forward-looking statements contained in this press release speak only as of the date on which they were made. Regulus undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.


'/>"/>
SOURCE Regulus Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Regulus Reports Second Quarter 2013 Financial Results and Recent Highlights
2. Regulus Announces Timing for Second Quarter 2013 Financial Results Webcast and Conference Call
3. Regulus Names Stelios Papadopoulos, Ph.D. as Chairman of its Board of Directors
4. Regulus to Present at Deutsche Bank 38th Annual Healthcare Conference
5. Regulus Provides Update on Road to the Clinic Strategy and Reports First Quarter 2013 Financial Results and Recent Highlights
6. Regulus Announces Timing for First Quarter 2013 Financial Results Webcast and Conference Call
7. Regulus Appoints William H. Rastetter, Ph.D. to its Board of Directors
8. Regulus to Present at Future Leaders in the Biotech Industry Conference
9. Regulus to Present at Cowen and Company 33rd Annual Healthcare Conference
10. Regulus Reports Fourth Quarter and Year-End 2012 Financial Results and Highlights
11. Regulus Announces Timing for Fourth Quarter and Year-End 2012 Financial Results Webcast and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2017)...  ValGenesis Inc., the global leader in Enterprise ... announce the appointment of Dr. Ajaz Hussain ... Directors and Chairman of Advisory Board beginning September ... to manage their entire validation lifecycle process electronically ... process. Furthermore, ValGenesis VLMS enables rigorous compliance, helps ...
(Date:9/9/2017)... , Sept. 8, 2017 Dealmed Medical ... independent supplier of medical equipment, supplies, drugs, vaccines, and ... has entered into an agreement to acquire Vantage Medical ... based in Holtsville, New York . ... in supplying new and emerging medical practices, will operate ...
(Date:9/7/2017)... , Sept. 7, 2017  Eli Lilly and ... actions to streamline operations to more efficiently focus ... its cost structure. Global workforce reductions, including those ... expected to impact approximately 3,500 positions. ... expects annualized savings of approximately $500 million that ...
Breaking Medicine Technology:
(Date:9/25/2017)... ... 25, 2017 , ... Nissar A. Darmani, PhD, has been awarded a record ... chemotherapy-evoked nausea and vomiting. Dr. Darmani is Associate Dean of Basic Medical Sciences ... grant is from the National Cancer Institute (NCI) arm of the National Institutes of ...
(Date:9/25/2017)... ... September 25, 2017 , ... The Byron Eaton Agency, a Birmingham based ... region, is organizing a local charity drive to send money and support to families ... of water have fallen on Houston as a result of Hurricane Harvey, raising water ...
(Date:9/25/2017)... ... September 25, 2017 , ... Introducing Panther, the revolutionary new iPhone case ... platform Kickstarter seeking support for the #WarOnGrime. , Fact: iPhones are 18 ... shockingly revolting, yet true. The Panther iPhone cases are the first weapon in the ...
(Date:9/25/2017)... (PRWEB) , ... September 25, 2017 , ... ... , an international competition, were announced on Friday, September 22 during a gala ... the human resources professionals, teams, achievements and HR-related products and suppliers who help ...
(Date:9/25/2017)... ... 25, 2017 , ... Catalent Pharma Solutions, the leading global ... health products, today announced that two of its leading biologics analytical experts will ... conferences. , At the BEBPA 10th Annual Bioassay Conference, to be held at ...
Breaking Medicine News(10 mins):